CALYPTE BIOMEDICAL CORP

CIK:0000899426|SEC Filings

Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Revenues:
Product sales	$ 230	$ 579
Operating costs and expenses:
Cost of product sales	216	417
Research and development expenses	259	296
Selling, general and administrative expenses	710	839
Total operating expenses	1,185	1,552
Loss from operations	(955)	(973)
Interest expense, net (non-cash expense of ($122) and ($121) in 2012 and 2011, respectively)	(122)	(121)
Other income, net	1	223
Net loss before income taxes	(1,076)	(871)
Benefit for income taxes	0	178
Net loss	$ (1,076)	$ (693)
Net loss per share (basic and diluted) (in Dollars per share)	$ (0.002)	$ (0.001)
Weighted average shares used to compute net income (loss) per share (basic and diluted) (in Shares)	666,869	545,854

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net loss from continuing operations	$ (1,076)	$ (693)
Adjustments to reconcile net loss to operating activities:
Depreciation and amortization	165	198
Non-cash interest expense attributable to:
Dividends on mandatorily redeemable Series A preferred stock	120	120
Stock-based employee compensation expense	8	(2)
Changes in operating assets and liabilities:
Accounts receivable	4	13
Inventory	30	78
Prepaid expenses and other current assets	2	16
Accounts payable, accrued expenses and other current liabilities	65	(173)
Net cash used in operating activities	(682)	(443)
Cash flows from investing activities:
Purchases of equipment		(5)
Net cash used in investing activities		(5)
Cash flows from financing activities:
Principal payments on notes payable	(28)	(18)
Proceeds from shareholder advances	715	397
Net cash provided by financing activities	687	379
Change in cash	5	(69)
Cash at beginning of the year	10	79
Cash at end of the year	15	10
Conversion of advances from related party into common stock		680
Conversion of related party liability into common stock	$ 914

Consolidated Balance Sheets (USD $)	Dec. 31, 2012	Dec. 31, 2011
Current assets:
Cash	$ 15,000	$ 10,000
Accounts receivable	4,000	8,000
Inventory, net of allowance of $35 and $0 at December 31, 2012 and 2011, respectively	156,000	186,000
Prepaid expenses	24,000	23,000
Total current assets	199,000	227,000
Property and equipment, net of accumulated depreciation of $397 and $375 at December 31, 2012 and 2011, respectively	22,000	44,000
Intangible assets, net of accumulated amortization of $1,000 and $857 at December 31, 2012 and 2011, respectively	1,531,000	1,674,000
Other assets	14,000	17,000
Total assets	1,766,000	1,962,000
Current liabilities:
Accounts payable and accrued expenses	2,062,000	1,999,000
Advances from shareholder	1,112,000	397,000
Liability with related party		914,000
4% Note payable, including accrued interest of $8 and $6 at December 31, 2012 and 2011, respectively	19,000	45,000
12% Convertible debentures payable	60,000	60,000
Total current liabilities	3,253,000	3,415,000
Mandatorily redeemable Series A preferred stock, $0.001 par value; no shares authorized at December 31, 2012 and 2011; 100,000 shares issued and outstanding at December 31, 2012 and 2011; aggregate redemption and liquidation value of $1,000 plus cumulative dividends	3,776,000	3,656,000
Total liabilities	7,029,000	7,071,000
Commitments and contingencies
Stockholders’ deficit:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.03 par value; 800,000,000 shares authorized at December 31, 2012 and 2011; 700,168,157 and 547,826,416 shares issued and outstanding as of December 31, 2012 and 2011, respectively	16,163,000	15,249,000
Additional paid–in capital	159,755,000	159,747,000
Other comprehensive income (loss)	(1,000)	(1,000)
Accumulated deficit	(181,180,000)	(180,104,000)
Total stockholders’ deficit	(5,263,000)	(5,109,000)
Total liabilities and stockholders’ deficit	1,766,000	1,962,000
4% Note Payable [Member]
Current liabilities:
4% Note payable, including accrued interest of $8 and $6 at December 31, 2012 and 2011, respectively		$ 39,000